CrushSCI.com
Journal Selection & Manuscript Polishing Services
BMC CANCER journal cover Medicine
Back to journal directory

Review Cycle Records

BMC CANCER

Springer SCIE OA
2026 Emerging Zone 22025 CAS Zone 32025 JCR Q2
154.9Average days
100Median days
35Fastest days
390Longest days
2,1032025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

43 days

Development and internal validation of machine learning-based prognostic prediction models for radical gastrectomy: a multidimensional risk stratification study

AuthorsJun Wu; Luqing Zhou; Haidi Chang; Tian Qin; Junxuan Zhu; Xuhui Liao

Affiliations1. Department of Pathology, The First Affiliated Hospital of Lishui University, Lishui People’s Hospital, Lishui City, China; 2. Guangzhou LBP Medical Technology Co., Ltd., Guangzhou, China

Source PDF DOI Publisher page
79 days

Genomic alterations and co-mutation patterns in advanced NSCLC: a real-world DNA-based NGS study in a large Turkish cohort

AuthorsAysu Sadioglu; Ozgur Ekinci; Nalan Akyurek

Affiliations1. Department of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey; 2. Department of Pathology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Türkiye

Source PDF DOI Publisher page
86 days

NNMT-associated metabolic–thromboinflammatory–immune co-activation in heterogeneous CTC clusters: a hypothesis-generating computational framework”

AuthorsJiayang Gong; Zhe Wang; Yun Shi; Minlan Ren; Tingting Li; Gang Li; Rui Peng

Affiliations1. Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital &, Jiangsu Institute of Cancer Research, Nanjing, China; 2. Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

Source PDF DOI Publisher page
175 days

Patients’ and oncologists’ perspectives on shared decision-making and treatment communication in HR+/HER2 − advanced breast cancer: a multicountry survey

AuthorsAlessandra Fabi; Andrea Botticelli; Saverio Cinieri; Gilles Freyer; José Angel García-Sáenz; Angel Guerrero-Zotano; Wolfgang Janni; Tatiana Massarrah Sánchez; Thibaut Reverdy; Michael Untch; Julien Péron

Affiliations1. Unità Medicina di Precisione in Senologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2. Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy; 3. UOSD Breast Cancer and Innovative Therapies, Rome, Italy; 4. Oncologia Medica and Breast Unit, Ospedale Perrino, Brindisi, Italy; 5. Department of Medical Oncology, Lyon University Hospital Cancer Institute, Lyon1 University, Lyon, France; 6. Centro Integral Oncológico (CINOC), Hospital Clínico San Carlos, Madrid, Spain; 7. Spanish Research Group in Breast Cancer. Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain; 8. Department of Obstetrics and Ginecology, Universitätsklinikum Ulm, Ulm, Germany; 9. Medical Oncology Research Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 10. Department of Medical Oncology, , Hôpital Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Laboratoire RESHAPE U1290 Inserm-UCBL, Lyon, France; 11. Clinic for Gynecology, Gynecologic Oncology, and Obstetrics, Interdisciplinary Breast Cancer Center, Medical School Berlin, Berlin, Germany

Source PDF DOI Publisher page
177 days

Enhancing prediction of pathological complete response to neoadjuvant immunotherapy in non-small cell lung cancer by whole-lung radiomics

AuthorsXiaoting Cai; Jingyi Yang; Jiahui E; Dianzhe Wang; Fangyuan Qu; Qiliang Wang; Zhuo Ning; Fan Liu; Yicai Zhang; Bole Gao; Bingsheng Sun; Ying Liu

Affiliations1. Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Tianjin’s Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; 2. Department of Radiology, Shandong Cancer Hospital and Institute, Affiliated to Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 3. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Tianjin’s Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Source PDF DOI Publisher page
390 days

Shikonin as a Parkin-dependent hypoxia-selective agent against triple-negative breast cancer identified by machine learning

AuthorsZichen Niu; Xuegang Niu

Affiliations1. The High School Affiliated to Renmin University of China, Beijing, P.R. China; 2. Southern Medical Branch of PLA General Hospital, Beijing, P.R. China

Source PDF DOI Publisher page
96 days

Improved oral health in head and neck cancer survivors (OHHNC study): a study protocol for a multicentre two-armed randomised controlled trial

AuthorsSandra Einarsson; Annica Almståhl; Hanna Gyllensten; Mats Sjöström; Lena Mårell; Ove Björ; Linda Marklund; Lovisa Farnebo; Göran Laurell; Ylva Tiblom Ehrsson

Affiliations1. Department of Food, Nutrition and Culinary Science, Umeå University, Umeå, Sweden; 2. Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden; 3. Department of Oral Health, Faculty of Odontology, Malmö University, Malmö, Sweden; 4. Institute of Health and Care Sciences Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden; 5. Department of Odontology, Oral and Maxillofacial surgery, Umeå University, Umeå, Sweden; 6. Department of Odontology, Orofacial Medicine, Umeå University, Umeå, Sweden; 7. Department of Diagnostics and Interventions/Oncology, Umeå University, Umeå, Sweden; 8. Department of Surgical Sciences, Section of Otorhinolaryngology and Head and Neck Surgery, Uppsala University, Uppsala, Sweden; 9. Department of Clinical Sciences, Division of ENT Diseases, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; 10. Medical Unit Head Neck, Lung and Skin Cancer, Karolinska University Hospital, Stockholm, Sweden; 11. Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Division of Sensory Organs and Communication, Linköping University, Linköping, Sweden; 12. Department of Otorhinolaryngology, Region Östergötland Anesthetics, Operations, and Specialty Surgery Center, Linköping, Sweden

Source PDF DOI Publisher page
97 days

eGDR and gastrointestinal cancer mortality in the UK Biobank: a prospective cohort study

AuthorsChuang Yang; Patrick S. Plum; Thomas Ebert; Jeanette Köppe; Ines Gockel; René Thieme

Affiliations1. Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany; 2. Department of Thyroid Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China; 3. Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany; 4. Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany; 5. Department of Epidemiology and Biostatistics, Public and Global Health, Medical University Lausitz – Carl Thiem, Cottbus, Germany; 6. Department of Visceral Surgery, Clarunis – Universitäres Bauchzentrum Basel, Basel, Switzerland

Source PDF DOI Publisher page
93 days

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [ 225 Ac]Ac-/[ 177 Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study

AuthorsMariam Amghar; Thomas Hielscher; Tobias Rausch; Hilal Özgür; Ulrike Bauder-Wüst; Hendrik Rathke; Frank Bruchertseifer; Alfred Morgenstern; Mareike Roscher; Vladimír Beneš; Clemens Kratochwil; Martina Benešová-Schäfer

Affiliations1. Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2. Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3. Genomics Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany; 4. Cantonal Hospital Grisons, Chur, Switzerland; 5. Department of Nuclear Medicine, University Hospital, Heidelberg, Germany; 6. European Commission, Joint Research Centre (JRC), Karlsruhe, Germany; 7. Service Unit Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Heidelberg, Germany

Source PDF DOI Publisher page
100 days

A combined PAX1/JAM3 methylation and HPV viral load model for exploratory risk stratification of ≥CIN2 among women with positive cervical screening results

AuthorsYing Zhang; Shuai Chen; Yu Jiang; Lina Zhang

Affiliations1. Changzhou Maternal and Child Health Care Hospital, Changzhou Key Laboratory of Maternal and Child Health Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou, China

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.